期刊文献+

吸入伊洛前列素对先天性心脏病患儿术后肺动脉高压的治疗作用 被引量:3

Therapeutic effect of inhaled Iloprost on pediatric pulmonary hypertension after congenital heart disease operation
原文传递
导出
摘要 目的评价吸入伊洛前列素对先天性心脏病术后肺动脉高压的疗效,并初步探讨其机制。方法以中国医学科学院阜外心血管病医院小儿心脏中心PICU收治的体外循环下双心室矫治手术后合并肺动脉高压13例患儿为研究对象,在术后48h内常规治疗的基础上,给予有效剂量伊洛前列素25ng/(kg·min),每次吸入10min,每4小时1次。观察患儿的血流动力学改变,采用酶联免疫吸附法检测血浆cAMP和cGMP浓度。结果13例患儿平均年龄(17.88±12.56)个月,平均体质量(9.29±3.59)kg。治疗前右房压、肺动脉收缩压、肺动脉收缩压/主动脉收缩压比值分别是(11.5±1.41)mmHg(1mmHg=0.133kPa)、(61.64±13.6)mmHg和0.66±0.16;治疗后20min分别降至(9.88±1.88)mmHg、(47.67±12.18)mmHg和0.52±0.15;治疗前后差异均有显著性(P〈0.01)。治疗后120min伊洛前列素疗效仍然存在。治疗前患儿血浆cAMP浓度为(335.75±127.31)μg/L,治疗后20min升至(519.68±148.54)μg/L,治疗前后差异有显著性(P〈0.01)。治疗前后血压、呼吸机条件和血浆cGMP浓度没有明显变化(P〉0.05)。结论对于先天性心脏病术后合并肺动脉高压患儿,吸入伊洛前列素可以显著降低肺动脉压力、改善肺循环血流动力学状态,可能与增高血浆cAMP浓度有关系。吸入伊洛前列素对体循环和呼吸功能影响小,未观察到明显不良反应。 Objective To study the therapeutic effects of inhaled iloprost on pediatric pulmonary hypertension after congenital heart disease operation and to investigate the mechanisms of iloprost. Methods Thirteen patients of postoperative pulmonary hypertension were given effective dose of iloprost 25 ng/( kg · min), 10 rain every time,every 4 hours for 48 h after the surgery. We used the 24 h cardiac monitoring and ultrasonic cardiography for hemodynamical monitoring. We examined the blood cAMP and cGMP by ELISA assay. Results The patients were ( 17. 88 ± 12. 56 ) months old with average weight of (9. 29 ± 3.59 ) kg. The right atrial pressure, systolic pulmonary arterial pressure, systolic pulmonary arterial pressure/systolic blood pressure were( 11.5± 1.41 )mm Hg, (61.64 ± 13.6) mm Hg and 0. 66 ±0. 16 before the treatment and they were (9. 88 ± 1.88) mm Hg, (47.67 ± 12. 18) mm Hg and 0. 52 ±0. 15 at the time point of 20 min after the treatment. For all the three parameters, there were significant differences before and after treatment. The effect of iloprost continues to 120 min later. The cAMP level was(335. 75 ± 127. 31 ) μg/L before iloprost inhalation and increased to(519. 68 ±148.54) μg/L at the time point of 20 min after inhaling iloprost, showing a significant difference( P 〈 0. 01 ). Blood pressure, cGMP level and ventilator parameters showed no notable difference before and after the treatment. Conclusion Inhaled iloprost significantly improves pulmonary hemodynamics in children with pulmonary hypertension after congenital heart disease operation, which might be achieved by increasing the blood cAMP. However, systemic blood pressure and respiratory function keep unaffected after iloprost inhalation.
出处 《中国小儿急救医学》 CAS 2009年第3期231-233,共3页 Chinese Pediatric Emergency Medicine
关键词 先天性心脏病 伊洛前列素 血浆CAMP 儿童 Congenital heart disease Inhaled iloprost Blood cAMP Child
  • 相关文献

参考文献13

  • 1Brown KL,Ridout DA ,Goldman AP ,et al. Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med,2003,31 ( 1 ) :28-33.
  • 2Thcodoraki K, Rcllia P, Thanopoulos A, et al. Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth ,2002,49 (9) :963-967.
  • 3Rashid A, Ivy D. Severe paediatric pulmonary hypertension: new management strategies. Arch Dis Child,2005,90( 1 ) :92-98.
  • 4Celermajer DS, Cullan S, Dcanfield JE. Impairment of endothelium dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation, 1993,87 (2) :440-446.
  • 5TuUoh RM. Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr Res Rev, 2005,6 (3) :174-180.
  • 6Pepkc-Zaba l,Higcnbottam TW, Dinh XA, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet, 1991,338 (8776) : 1173-1174.
  • 7Miller OI,Tang SF,Keech A,et al. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomized double-blind study. Lancet, 2000,356 ( 9240 ) : 1464-1469.
  • 8Miller OI, Tang SF, Keeeh A, et al. Rebound pulmonary hypertension on withdrawal from inhaled NO. Lancet, 1995,346 (8966) :51-52.
  • 9Bizzarro M, Gross I. Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease. Cochrane Database Syst Rev ,2005 (4) : CD005055.
  • 10Olschewski H, Walmrath D, Sehermuly R, et al. Aerosolized prostaeyclin and iloprost in severe pulmonary hypertension. Ann Int Med,1996,124(9) :820-824.

同被引文献57

  • 1Badesch DB,Champion HC,Sanchez MA,Hoeper MM,LoydJE,Manes A,et al.Diagnosis and assessment of pulmonary arte-rial hypertension[J].J Am Coll Cardiol,2009,54(1 Suppl):S55-S66.
  • 2Fraisse A,Jais X,Schleich JM,di Filippo S,Maragnès P,Beghetti M,et al.Characteristics and prospective 2-year follow-upof children with pulmonary arterial hypertension in France[J].Arch Cardiovasc Dis,2010,103(2):66-74.
  • 3Rich JD,Shah SJ,Swamy RS,Kamp A,Rich S.Inaccuracy ofDoppler echocardiographic estimates of pulmonary artery pressuresin patients with pulmonary hypertension:implications for clinicalpractice[J].Chest,2011,139(5):988-993.
  • 4McLaughlin VV,Archer SL,Badesch DB,Barst RJ,Farber HW,Lindner JR,et al.ACCF/AHA 2009 expert consensus documenton pulmonary hypertension:a report of the American College ofCardiology Foundation Task Force on Expert Consensus Documentsand the American Heart Association:developed in collaborationwith the American College of Chest Physicians,American ThoracicSociety,Inc.,and the Pulmonary Hypertension Association[J].Circulation,2009,119(16):2250-2294.
  • 5Agarwal R,Gomberg-Maitland M.Current therapeutics and practi-cal management strategies for pulmonary arterial hypertension[J].Am Heart J,2011,162(2):201-213.
  • 6Bowyer JJ,Busst CM,Denison DM,Shinebourne EA.Effect oflong term oxygen treatment at home in children with pulmonaryvascular disease[J].Br Heart J,1986,55(4):385-390.
  • 7Barst RJ,Maislin G,Fishman AP.Vasodilator therapy for primarypulmonary hypertension in children[J].Circulation,1999,99(9):1197-1208.
  • 8Barst RJ,Rubin LJ,Long WA,McGoon MD,Rich S,BadeschDB,et al.A comparison of continuous intravenous epoprostenol(prostacyclin)with conventional therapy for primary pulmonaryhypertension.The Primary Pulmonary Hypertension Study Group[J].N Engl J Med,1996,334(5):296-302.
  • 9Lammers AE,Hislop AA,Flynn Y,Haworth SG.Epoprostenoltreatment in children with severe pulmonary hypertension[J].Heart,2007,93(6):739-743.
  • 10Mathier MA,McDevitt S,Saggar R.Subcutaneous treprostinil inpulmonary arterial hypertension:practical considerations[J].JHeart Lung Transplant,2010,29(11):1210-1217.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部